Sarepta Forms Strategic Advisory Board
This article was originally published in Scrip
Executive Summary
Sarepta Therapeutics Inc., a developer of RNA-targeted therapies, has formed a strategic and scientific advisory board (SSAB) with three key appointments: Dr Louis Kunkel, Dr Beverly Davidson, and Dr Jeffrey Chamberlain. The SSAB will work closely with Sarepta's management team to advance the company's platform technology in Duchene muscular dystrophy, identify multiple new applications for Sarepta's proprietary PMO chemistry in the neuromuscular rare disease and infectious disease areas, as well as provide insight on novel technologies to complement the company's pipeline.